Respiratory Distress Syndrome of the Newborn – Causes & Treatment
Respiratory Distress Syndrome of the Newborn is a serious lung condition in premature infants caused by surfactant deficiency, requiring intensive medical care immediately after birth.
Wissenswertes über "Respiratory Distress Syndrome of the Newborn"
Respiratory Distress Syndrome of the Newborn is a serious lung condition in premature infants caused by surfactant deficiency, requiring intensive medical care immediately after birth.
What is Respiratory Distress Syndrome of the Newborn?
Respiratory Distress Syndrome (RDS) of the newborn, also known as Hyaline Membrane Disease, is a life-threatening lung condition that primarily affects premature infants born before 34 weeks of gestation. It is one of the most common causes of breathing difficulties in newborns and typically requires immediate neonatal intensive care. Without prompt treatment, the condition can be fatal.
Causes
The primary cause of RDS is a deficiency of surfactant – a natural substance that coats the inner surface of the alveoli (tiny air sacs in the lungs) and prevents them from collapsing during exhalation. Surfactant is not produced in sufficient quantities until approximately 24 to 28 weeks of gestation. In premature infants, the lungs are not yet fully mature, resulting in inadequate surfactant levels.
- Premature birth before 34 weeks of gestation (primary risk factor)
- Male sex of the newborn (higher risk compared to female preterm infants)
- Maternal diabetes mellitus (delays lung maturation)
- Multiple pregnancies (twins, triplets)
- Genetic predisposition and family history
- Caesarean section without prior labor (absence of labor-induced maturation signals)
Symptoms
Symptoms of RDS typically appear shortly after birth, often within the first few hours of life. Common signs include:
- Rapid, labored breathing (tachypnea)
- Visible retractions of accessory breathing muscles (between the ribs or at the neck)
- Grunting sounds during exhalation (expiratory grunting)
- Bluish discoloration of the skin and lips (cyanosis) due to low oxygen levels
- Flaring of the nostrils during inhalation
- Reduced muscle tone and weak reflexes
Diagnosis
Diagnosis is made clinically through observation and confirmed with several investigations:
- Physical examination: Assessment of breathing rate, retractions, and skin color
- Blood gas analysis: Measurement of oxygen and carbon dioxide levels in the blood
- Chest X-ray: Characteristic ground-glass appearance (reticulogranular pattern) of the lungs
- Pulse oximetry: Continuous monitoring of blood oxygen saturation
- Amniocentesis (before birth, if indicated): Assessment of fetal lung maturity
Treatment
Treatment of RDS takes place in a neonatal intensive care unit (NICU) and involves several key interventions:
Surfactant Replacement Therapy
The most important treatment is the direct administration of artificial or animal-derived surfactant into the lungs of the premature infant via a thin tube (endotracheal tube). This rapidly and significantly improves lung function. Surfactant therapy is initiated as early as possible after birth.
Respiratory Support
Many premature infants require additional breathing support:
- CPAP (Continuous Positive Airway Pressure): A gentle air pressure delivered via a nasal mask to keep the airways open
- Mechanical ventilation: In severe cases, the infant is intubated and supported by a ventilator
- Oxygen therapy: Supplemental oxygen to treat cyanosis and maintain adequate saturation
Prenatal Prevention
When preterm birth is anticipated, mothers receive corticosteroids (e.g., betamethasone) by injection. These medications accelerate fetal lung maturation and can significantly reduce the risk and severity of RDS in the newborn.
Additional Supportive Care
- Thermoregulation in an incubator
- Intravenous fluids and nutrition via a nasogastric tube
- Continuous monitoring of heart rate, breathing, and oxygen saturation
- Management of associated complications (e.g., infections, patent ductus arteriosus)
Prognosis and Complications
Thanks to modern treatment approaches, the prognosis for RDS has improved considerably. Most affected infants survive and recover well. However, severe cases may lead to complications, including:
- Bronchopulmonary dysplasia (chronic lung disease of prematurity)
- Intraventricular hemorrhage (bleeding in the brain)
- Retinopathy of prematurity (eye damage related to oxygen therapy)
- Long-term developmental delays in very preterm infants
References
- Sweet DG et al. – European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2022 Update. Neonatology, 2023; 120(1): 3–23.
- World Health Organization (WHO) – Preterm birth. Fact sheet. Geneva: WHO, 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/preterm-birth
- Jobe AH, Bancalari E – Bronchopulmonary Dysplasia. American Journal of Respiratory and Critical Care Medicine, 2001; 163(7): 1723–1729.
Best-selling products
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryCopper peptide
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Cologne list
Calorie content
Related search terms: Respiratory Distress Syndrome of the Newborn + Neonatal Respiratory Distress Syndrome + Infant Respiratory Distress Syndrome + RDS Newborn + Hyaline Membrane Disease